8-K - Editas Medicine, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Editas Medicine announced that the U.S. Patent and Trademark Office reaffirmed a prior decision favoring the Broad Institute in a CRISPR/Cas9 patent interference case on March 26, 2026. This outcome reinforces the company's intellectual property foundation for developing CRISPR/Cas9-based medicines, including EDIT-401.

Key Takeaways

1The U.S. Patent and Trademark Office reaffirmed the Patent Trial and Appeal Board's decision favoring the Broad Institute in the CRISPR/Cas9 patent interference on March 26, 2026.

2The patent interference involves specific patents for CRISPR/Cas9 editing in human cells between CVC (University of California, University of Vienna, Emmanuelle Charpentier) and Broad (Broad Institute, MIT, Harvard University).

3This is the PTAB's third favorable decision determining Broad was first to invent CRISPR/Cas9 for gene editing in eukaryotic cells, including human cells.

4CVC retains the right to appeal the decision to the U.S. Court of Appeals for the Federal Circuit.

5The CRISPR/Cas9 patents at issue are exclusively licensed to Editas Medicine for development and commercialization of CRISPR/Cas9-based medicines.

6Editas Medicine's foundational intellectual property includes issued patents covering fundamental aspects of both CRISPR/Cas12a and CRISPR/Cas9 gene editing in all human cells.

Current Report Details

Event Type

Regulation Fd

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “Filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “

Regulation Fd

8.01

Other Events. On March 26, 2026, the U.S. Patent and Trademark Office reaffirmed the Patent Trial and Appeal Board’s (“PTAB’s”) previous decision favoring the B

Other Event

9.01

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by the Company on March 27, 2026* 104 Cover Page Interactive D

Exhibits Only

Source Document

Exhibits (2)

8-K

EX-99